Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 6/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | ANO1 | Q5XXA6 | 2/20 | 1.00 |
| ▸ | ANO2 | Q9NQ90 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.70 |
| ▸ | NPC1 | O15118 | 3/20 | 0.61 |
| ▸ | RAB9A | P51151 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 5/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.56 |
| ▸ | CRHBP | P24387 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14085827 | 0.75 | SMN1; SMN2 (0.81) | MEN1KMT2ALMNAMAPK1NPC1 | |
| SCHEMBL10814398 | 0.70 | MEN1 (0.83) | MEN1KMT2ALMNAMAPK1NPC1 | |
| SCHEMBL10922779 | 0.70 | GSTO1 (0.74) | MEN1KMT2ALMNAMAPK1NPC1 | |
| SCHEMBL21484832 | 0.69 | SMN1; SMN2 (0.71) | MEN1KMT2ALMNAMAPK1NPC1 | |
| Tioxamast SCHEMBL2111615 | 0.69 | LMNA (0.67) | MEN1KMT2ALMNAMAPK1TDP1 | |
| SCHEMBL28199635 | 0.69 | RAB9A (0.72) | MEN1KMT2ALMNAMAPK1NPC1 | |
| SCHEMBL18456567 | 0.69 | SMN1; SMN2 (0.77) | MEN1KMT2ALMNAMAPK1NPC1 | |
| SCHEMBL28481057 | 0.69 | TDP1 (0.68) | MEN1KMT2ALMNAMAPK1ANO1 | |
| SCHEMBL5798106 | 0.68 | TDP1 (0.60) | MEN1KMT2ALMNAMAPK1ANO1 | |
| SCHEMBL11137982 | 0.68 | MEN1 (0.70) | MEN1KMT2ALMNAMAPK1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113117088-B | Use of inhibitors of calcium activated chloride channels in tumor immunotherapy | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 2023-08-08 | — | — | CN | claimed |
| CN-120837500-A | Application of inhibitor T16Ainh-A01 in preparation of medicines for preventing or treating porcine reproductive and respiratory syndrome virus infection | 河南大学 | 2025-10-28 | — | — | CN | disclosed |
| CN-120837500-A | Application of inhibitor T16Ainh-A01 in preparation of medicines for preventing or treating porcine reproductive and respiratory syndrome virus infection | 河南大学 | 2025-10-28 | — | — | CN | disclosed |
| WO-2025110778-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING HEAD AND NECK CANCER | 주식회사 에스트리온 | 2025-05-30 | — | — | WO | disclosed |
| WO-2025110777-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF BREAST CANCER | 주식회사 에스트리온 | 2025-05-30 | — | — | WO | disclosed |
| WO-2025056091-A2 | USE OF IFP35 PROTEIN FAMILY IN EVALUATION OF EFFICACY OF TUMOR IMMUNOTHERAPY | 中山大学 | 2025-03-20 | — | — | WO | disclosed |
| US-20240317877-A1 | ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODY HAVING IMPROVED BLOOD-BRAIN-BARRIER PERMEABILITY, AND MULTI-SPECIFIC ANTIBODY AND PHARMACEUTICAL COMPOSITION WHICH USE SAME | IUCF-HYU (INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY) (KR) | 2024-09-26 | — | — | US | disclosed |
| WO-2024155066-A1 | ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODY WITH IMPROVED BLOOD-BRAIN-BARRIER PERMEABILITY, AND MULTISPECIFIC ANTIBODY AND PHARMACEUTICAL COMPOSITION USING SAME | 주식회사 시그널바이오 | 2024-07-25 | — | — | WO | disclosed |
| CN-118001289-A | Application of scutellarin (Scu) to gastric cancer AGS cell TMEM16A channel current | 武汉科技大学 | 2024-05-10 | — | — | CN | disclosed |
| EP-4351739-A2 | COMPOSITIONS AND METHODS FOR CONTROLLING SWEAT PRODUCTION | Unilever IP Holdings B.V. (NL) | 2024-04-17 | — | — | EP | disclosed |
| WO-2022258385-A2 | COMPOSITIONS AND METHODS FOR CONTROLLING SWEAT PRODUCTION | UNILEVER IP HOLDINGS B.V. (NL) | 2022-12-15 | — | — | WO | disclosed |
| US-20220193041-A1 | NOVEL COMPOUND AND METHOD FOR PREVENTING OR TREATING OF RESPIRATORY DISEASES COMPRISING THE SAME AS AN ACTIVE INGREDIENT | Yonsei University, University - Industry Foundation (UIF) (KR) | 2022-06-23 | — | — | US | disclosed |
| CN-114642651-A | Photothermal response drug-loaded nanoparticle and preparation and application thereof | 河北工业大学 | 2022-06-21 | — | — | CN | disclosed |
| US-11358947-B2 | Substituted 2-acylamino-cycloalkylthiophene-3-carboxylic acid arylamides as inhibitors of calcium-activated chloride channel TMEM16A | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-06-14 | — | — | US | disclosed |
| US-11274074-B2 | Pharmaceutical composition for ANO1 antagonist with anticancer activity | INDUSTRY-ACADEMIC COOPERATION FOUNDATION YONSEI UNIVERSITY (KR) | 2022-03-15 | — | — | US | disclosed |
| WO-2022023380-A2 | ASSAY | KING'S COLLEGE LONDON (GB) | 2022-02-03 | — | — | WO | disclosed |
| US-20210156844-A1 | TMEM16A Modulation for Diagnostic or Therapeutic Use in Pulmonary Hypertension (PH) | BAYER AKTIENGESELLSCHAFT (DE) | 2021-05-27 | — | — | US | disclosed |
| EP-3618861-A1 | TMEM16A MODULATION FOR DIAGNOSTIC OR THERAPEUTIC USE IN PULMONARY HYPERTENSION (PH) | Bayer Aktiengesellschaft (DE) | 2020-03-11 | — | — | EP | disclosed |
| WO-2018202471-A1 | TMEM16A MODULATION FOR DIAGNOSTIC OR THERAPEUTIC USE IN PULMONARY HYPERTENSION (PH) | BAYER AKTIENGESELLSCHAFT (DE) | 2018-11-08 | — | — | WO | disclosed |
| US-20150056604-A1 | COMPOSITIONS AND METHODS FOR PRESERVING PLATELET FUNCTION | BIOVEC TRANSFUSION, LLC | 2015-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11274074-B2 | Pharmaceutical composition for ANO1 antagonist with anticancer activity | ANO1, ANO2, TMEM109 | MEN1 1890/4885KMT2A 3684/4885LMNA 3228/4885 |
| US-11358947-B2 | Substituted 2-acylamino-cycloalkylthiophene-3-carboxylic acid arylamides as inhibitors of calcium-activated chloride channel TMEM16A | TMEM161A, ANO2, TRPV6 | MEN1 1780/4885KMT2A 923/4885LMNA 2626/4885 |
| US-20210156844-A1 | TMEM16A Modulation for Diagnostic or Therapeutic Use in Pulmonary Hypertension (PH) | TMEM109, ANO1, ANO2 | MEN1 907/4885KMT2A 2397/4885LMNA 560/4885 |
| US-20220193041-A1 | NOVEL COMPOUND AND METHOD FOR PREVENTING OR TREATING OF RESPIRATORY DISEASES COMPRISING THE SAME AS AN ACTIVE INGREDIENT | EPX, CFTR, MPO | MEN1 3034/4885KMT2A 3803/4885LMNA 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.